Bio-Rad Laboratories (BIO) Current Deferred Revenue (2010 - 2022)

Bio-Rad Laboratories (BIO) has 13 years of Current Deferred Revenue data on file, last reported at $52.2 million in Q4 2022.

• Quarterly Current Deferred Revenue fell 26.48% year-over-year to $52.2 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $52.2 million (down 26.48% YoY) and the FY2022 annual result came in at $52.2 million, down 26.48% from the prior year.
• Current Deferred Revenue eased to $52.2 million in Q4 2022 per BIO's latest filing, from $71.0 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $71.0 million in Q4 2021 and bottomed at $26.9 million in Q4 2018.
• The 5-year median for Current Deferred Revenue is $42.5 million (2020), against an average of $44.5 million.
• The widest annual swing landed in 2021, when Current Deferred Revenue soared 67.06%; it then slipped 26.48% in 2022.
• Tracing BIO's Current Deferred Revenue over 5 years: stood at $26.9 million in 2018, then increased by 25.24% to $33.7 million in 2019, then rose by 25.98% to $42.5 million in 2020, then soared by 67.06% to $71.0 million in 2021, then fell by 26.48% to $52.2 million in 2022.
• Per Business Quant, the three latest BIO Current Deferred Revenue figures stand at $52.2 million (Q4 2022), $71.0 million (Q4 2021), and $42.5 million (Q4 2020).

Peer Comparison